Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “We had the strongest first quarter in our Company’s history, recording record Revenue and EBITDA. Our Revenue increased 17.4% and our EBITDA increased 57.3% from last year’s first quarter. While we benefited by more favorable winter weather conditions during this year’s quarter, our improved performance was also driven by strong contributions from our recent acquisitions and initiatives on the East Coast and overall same-center procedural volume growth of 2.3%.”

Dr. Berger continued, “We continue to grow our core markets through driving patient volumes with effective marketing programs, offering differentiated services, deploying cutting-edge technologies, encouraging alternate payment models (such as capitation) and establishing joint ventures with strong and entrepreneurial health systems. During the quarter, we announced the formation of our second California joint venture with Dignity Health in Ventura County, California. We also made progress with operationalizing our first East Coast capitation contract with Emblem Health and integrating our recently acquired Medical Arts Radiology acquisition in Long Island, New York.”

“Subsequent to quarter’s end, on April 1st, we completed the acquisition of Kern Radiology in Kern County, California. Kern operates 5 multimodality imaging centers, performs over 200,000 exams per year and earns over $25 million of Revenue on an annual basis. Additionally, on April 18th, we completed a financing which raised an incremental term loan of $100 million and added $20 million of additional capacity under our revolving credit facility. The financing affords us additional financial and operating flexibility to complete future tuck-in acquisitions and to establish new health system joint ventures in the future. We are very appreciative of the support and confidence we received from our long-standing lending group,” added Dr. Berger.

Financial Results

For the first quarter of 2019, RadNet reported Revenue of $271.5 million, Adjusted EBITDA(1) of $33.1 million and Net Loss of $3.7 million. Revenue increased $40.2 million (or 17.4%), Adjusted EBITDA(1) increased $12.1 million (or 57.3%) and Net Loss decreased $3.6 million, over the first quarter of 2018. Per share Net Loss for the first quarter was $(0.08), compared to $(0.15) in the first quarter of 2018, based upon a weighted average number of basic and diluted shares outstanding of 49.6 million shares in 2019 and 47.8 million shares in 2018.

Affecting Net Loss in the first quarter of 2019 were certain non-cash expenses and non-recurring items including: $4.5 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $631,000 of severance paid in connection with headcount reductions related to cost savings initiatives; and $975,000 of non-cash amortization of deferred financing costs and loan discounts related to financing fees paid as part of our existing credit facilities.

For the first quarter of 2019, as compared to the prior year’s first quarter, MRI volume increased 7.3%, CT volume increased 10.4% and PET/CT volume increased 7.2%. Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 7.6% over the prior year’s first quarter. On a same-center basis, including only those centers which were part of RadNet for both the first quarters of 2019 and 2018, MRI volume increased 3.2%, CT volume increased 4.5% and PET/CT volume decreased 3.7%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 2.3% over the prior year’s same quarter.

(a) Defined by the Company as Adjusted EBITDA(1) less total capital expenditures and cash paid for interest.(b) Net of proceeds from the sale of equipment, imaging centers and joint venture interests.

Dr. Berger highlighted, “We are on track to meet our guidance levels that we established upon reporting our 2018 fourth quarter and full-year financial results. We adjusted our cash interest expenses to properly incorporate the expected interest expense of New Jersey Imaging Network, which became a consolidated entity in the fourth quarter, and the recently completed incremental Term Loan.”

Conference Call for Today

Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its first quarter 2019 results on Thursday, May 9th, 2019 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

It is recommended that participants dial in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at http://public.viavid.com/index.php?id=134511 or http://www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10006819.

Regulation G: GAAP and Non-GAAP Financial Information

This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.

About RadNet, Inc.

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 335 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey and New York. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 7,800 employees. For more information, visit http://www.radnet.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning successfully integrating acquired operations, successfully achieving 2019 financial guidance, successfully developing and integrating new lines of business, continuing to grow its business by generating patient referrals and contracts with radiology practices, and receiving third-party reimbursement for diagnostic imaging services, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause the Company's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect RadNet's business and its financial results are detailed in its most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

**Capitation percentage has been calculated based upon its proportion of Revenue Under Capitation Arrangements in the period to Service Fee Revenue, Net of Contractual Allowances and Discounts plus Revenue Under Capitation Arrangements. After deducting the capitation percentage from 100%, all other payor class percentages are based upon a proportion to global payments received from consolidated imaging centers from that periods dates of services and excludes payments from hospital contracts, Breastlink, imaging center management fees, eRAD, Imaging on Call and other miscellaneous revenue.

RADNET PAYMENTS BY MODALITY *

First Quarter

Full Year

Full Year

Full Year

Full Year

2019

2018

2017

2016

2015

MRI

35.6%

35.2%

34.9%

34.7%

35.3%

CT

17.1%

16.5%

16.2%

15.8%

15.7%

PET/CT

5.7%

5.7%

5.2%

5.0%

5.1%

X-ray

8.5%

8.4%

8.9%

9.3%

9.6%

Ultrasound

12.5%

12.2%

12.1%

12.3%

11.5%

Mammography

14.8%

15.8%

16.3%

16.5%

16.4%

Nuclear Medicine

1.0%

1.1%

1.1%

1.2%

1.3%

Other

4.8%

5.1%

5.2%

5.2%

5.1%

100.0%

100.0%

100.0%

100.0%

100.0%

Note

* Based upon global payments received from consolidated Imaging Centers from that period's dates of service.

(1) The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.

Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

(2) As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest paid. Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.

Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.